by Keishi Foecke | Feb 18, 2026 | Blog Post
Life sciences mergers and acquisitions (M&A) activity gained momentum in late 2025, and that acceleration is expected to continue in 2026. This positive trend is vitally important for the many treatments and cures that depend on these partnerships to reach...
by Steve Strong | Feb 5, 2026 | Blog Post
New research presented at a Congressional staff briefing highlighted the strong, positive relationship between pharmaceutical mergers and acquisitions (M&A) and the launches of new drugs for patients. Research Finds that Pharmaceutical M&A Drives New, Novel...
by Keishi Foecke | Dec 19, 2025 | Blog Post
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences. As the leading advocacy coalition on life sciences M&A, PULSE educated stakeholders and...
by Keishi Foecke | Dec 10, 2025 | Blog Post
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem. As experts observe continued funding pressures on...
by Keishi Foecke | Nov 20, 2025 | Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series here....
by Keishi Foecke | Nov 6, 2025 | Blog Post
Despite decades of biomedical breakthroughs, 95% of the 7,000 identified rare diseases still lack an approved treatment or cure. While these diseases may be individually rare, they collectively impact 1 in 10 Americans. To address these unmet medical needs requires...
